S'abonner

Relevance of specific IgE antibody titer to the prevalence, severity, and persistence of asthma among 19-year-olds in northern Sweden - 18/04/17

Doi : 10.1016/j.jaci.2016.05.017 
Matthew S. Perzanowski, PhD a, , Eva Ronmark, PhD b, , Hayley R. James, BS c, , Linnea Hedman, PhD b, Alexander J. Schuyler, BS, BA c, Anders Bjerg, MD, PhD d, Bo Lundback, MD d, Thomas A.E. Platts-Mills, MD, PhD, FRS c,
a Mailman School of Public Health, Columbia University, New York, NY 
b Department of Public Health and Clinical Medicine, OLIN Unit, Umea University, Umea, Sweden 
c Division of Allergy and Immunology, University of Virginia, Charlottesville, Va 
d Department of Medicine/Krefting Research Center, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden 

Corresponding author: Thomas A. E. Platts-Mills, MD, PhD, FRS, Box 801355, Charlottesville, VA 22908.Box 801355CharlottesvilleVA22908

Abstract

Background

Although sensitization to indoor allergens is strongly associated with asthma, there are questions as to how this relates to asthma symptoms.

Objective

We sought to study the relevance of IgE antibodies to cat and dog allergens in an area in which (1) the climate discourages cockroach, fungal, and mite growth and (2) dander allergens are known to be present in schools and houses without animals.

Methods

IgE to 8 allergens was tested in 963 sera from a population-based study on 19-year-olds, and associations with asthma symptoms, diagnosis, and treatment were examined. In positive sera IgE to specific cat and dog allergens was also assayed.

Results

IgE specific for animal dander had the highest prevalence and strongest relationship to asthma diagnosis. Furthermore, asthma severity, as judged by the frequency of symptoms and use of treatment, was directly associated with the titer of IgE antibodies to animal dander. Among the 103 subjects who had current asthma at age 19 years, 50 had asthma before age 12 years. Among those 50, the odds ratios for asthma related to any IgE antibodies to animal dander or high-titer IgE antibodies (≥17.5 IU/mL) were 9.2 (95% CI, 4.9-17) and 13 (95% CI, 6.9-25), respectively. In multivariable analysis IgE antibodies to Fel d 1 and Can f 5 were each associated with current asthma.

Conclusion

High-titer IgE antibodies to cat and dog allergens were strongly associated with the diagnosis, severity, and persistence of asthma; however, a large proportion of patients with current asthma did not live in a house with a cat or dog.

Le texte complet de cet article est disponible en PDF.

Key words : IgE titer, IgE antibodies, mammalian allergen, asthma severity, cat ownership


Plan


 Supported by National Institutes of Health grants R01-AI-20565 and U19-AI-070364 to T.A.E.P.-M., as well as P30-ES-09089 to M.S.P., and grants to E.R. from the Swedish Heart-Lung Foundation, the Swedish Research Council, the Swedish Asthma-Allergy Foundation, the Swedish Foundation for Health Care Science and Allergy Research (Vårdal), Visare Norr, Umeå University, and Norrbotten County Council. Phadia/Thermo Fisher provided unrestricted support for IgE assays. Additional funding was provided by GlaxoSmithKline World Wide Epidemiology and ALK-Abelló (Hörsholm, Denmark).
 Disclosure of potential conflict of interest: E. Ronmark has received research support from the Swedish Heart-Lung Foundation, the Swedish Asthma-Allergy Foundation, the Swedish Research Council, Umeå University, Visare Norr, Norrbotten County Council, and GlaxoSmithKline. B. Lundback has received research support from the Swedish Heart-Lung Foundation, the Swedish Asthma-Allergy Foundation, the Swedish Research Council, Umeå University, Visare Norr, Norrbotten County Council, GlaxoSmithKline, and AstraZeneca and has participated in the advisory boards for and received lecture fees from AstraZeneca, GlaxoSmithKline, and Novartis. T. A. E. Platts-Mills has received research support from Thermo Fisher/Phadia. The rest of the authors declare that they have no relevant conflicts of interest.


© 2016  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 138 - N° 6

P. 1582-1590 - décembre 2016 Retour au numéro
Article précédent Article précédent
  • Airway hyperresponsiveness in chronic obstructive pulmonary disease: A marker of asthma-chronic obstructive pulmonary disease overlap syndrome?
  • Ruzena Tkacova, Darlene L.Y. Dai, Judith M. Vonk, Janice M. Leung, Pieter S. Hiemstra, Maarten van den Berge, Lisette Kunz, Zsuzsanna Hollander, Donald Tashkin, Robert Wise, John Connett, Raymond Ng, Bruce McManus, S.F. Paul Man, Dirkje S. Postma, Don D. Sin
| Article suivant Article suivant
  • A health care navigation tool assesses asthma self-management and health literacy
  • Luzmercy Perez, Knashawn H. Morales, Heather Klusaritz, Xiaoyan Han, Jingru Huang, Marisa Rogers, Ian M. Bennett, Cynthia S. Rand, Grace Ndicu, Andrea J. Apter

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.